Eli Lilly and Company (LLY) announced today that it has released new data on two of its cancer treatments, Verzenio (abemaciclib) and Jaypirca (ibrutinib). The data, which was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, shows that Verzenio and Jaypirca can significantly improve outcomes for patients with breast cancer and lymphoma, respectively.
Verzenio is a CDK4/6 inhibitor that is used to treat hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer. The new data from a Phase III trial showed that Verzenio, when used in combination with endocrine therapy, significantly improved progression-free survival (PFS) in patients with this type of breast cancer. Patients who received Verzenio had a median PFS of 28.9 months, compared to 22.4 months for patients who received endocrine therapy alone.
Jaypirca is a Bruton's tyrosine kinase (BTK) inhibitor that is used to treat relapsed or refractory mantle cell lymphoma (MCL). The new data from a Phase III trial showed that Jaypirca, when used in combination with bendamustine and rituximab, significantly improved overall survival (OS) in patients with this type of lymphoma. Patients who received Jaypirca had a median OS of 65.4 months, compared to 50.7 months for patients who received bendamustine and rituximab alone.
The data released by Eli Lilly today is further evidence of the progress that is being made in the fight against cancer. Verzenio and Jaypirca are two important new treatments that offer hope to patients with breast cancer and lymphoma.
In addition to the data on Verzenio and Jaypirca, Eli Lilly also presented data on other cancer treatments at ASCO. The company announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for approval of dostarlimab (Jemperli), a checkpoint inhibitor that is used to treat advanced endometrial cancer. Eli Lilly also presented data on its experimental drug, talazoparib, which is being developed as a treatment for BRCA1/2-mutated ovarian cancer.
The data presented by Eli Lilly at ASCO is a sign of the company's commitment to developing innovative cancer treatments. The company is working on a number of other promising cancer drugs, and it is likely to continue to make important contributions to the fight against cancer in the years to come.
People also ask
⚐ What are the top stocks to invest in right now?☵ What happens to stocks when they're delisted?